Facebook
  1. Home
  2. Insights
  3. Blog
  4. Biomarkers and breakthroughs

Biomarkers and breakthroughs: Accelerating clinical trials in neurodegenerative diseases

Neurodegenerative diseases like Alzheimer’s and Parkinson’s have long posed a challenge to clinical research. High failure rates, slow progression and complex pathology have made drug development in this space notoriously difficult. But a wave of innovation in biomarkers is changing the landscape and bringing new precision, speed and hope to patients and researchers alike.

Here, we build on the conversation explored in our recent webinar, Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases, moderated by ICON’s Prof. Peter Schueler, MD, Senior Vice President of Drug Development Solutions, Neurosciences & Immunology. We explore how biomarkers are reshaping trial design, diagnosis and patient outcomes, and the vital role of collaboration in driving innovation in this exciting field.

Biomarkers as the engine of innovation in CNS trials

Over the past decade, we have seen an explosion in biomarker development across fluid, imaging, genomic and digital domains. These tools are rapidly shifting from experimental to essential, moving the dial on central nervous system (CNS) therapies. The biomarkers breakthrough opened a door for deeper understanding of these complex pathologies, which has subsequently informed clinical trial design, from identifying the right patients to monitoring disease progression and measuring treatment response.

This shift is particularly impactful in CNS trials, where traditional endpoints often fail to capture subtle changes. Biomarkers offer earlier, more sensitive indicators of efficacy, enabling faster decisions and more targeted therapies.

From clinical syndromes to biology: Redefining diagnostic concepts

Diagnosis is the first step toward treatment. In CNS, even precise diagnosis is particularly challenging.

Historically, diagnosing neurodegenerative diseases relied heavily on clinical observation of symptoms. Memory loss, tremors or cognitive decline were used to categorise patients into broad syndromes like Alzheimer’s or Parkinson’s. While practical, this approach does not account for what we now know about CNS: that different biologies can present as the same syndrome. As such, the symptom focused diagnostics may lead to misclassification and inconsistent trial outcomes. 

For example, patients with corticobasal syndrome may have different underlying pathologies, which can now be identified using biomarkers. This enables targeted therapies based on biology rather than symptoms alone. Similarly, diagnosis of Alzheimer’s is now anchored in biological evidence, specifically the presence of amyloid beta and Tau pathology. This biological lens has revealed that many patients previously diagnosed with Alzheimer’s may not have the hallmark amyloid pathology, meaning they were unlikely to benefit from amyloid-targeting therapies. By refining inclusion criteria through biomarkers, trials can now focus on those most likely to respond, reducing noise and increasing statistical power.

In Parkinson’s research, new frameworks incorporate synuclein aggregation, neurodegeneration and genetic markers to define disease subtypes more accurately. These criteria are not yet agreed as standard in clinical research, but they are already influencing trial design and therapeutic strategy.

This redefinition of the core diagnostic concept now allows researchers to identify patients with confirmed disease mechanisms, differentiating the subtypes to better align patients with the right treatments. 

Precision, potential and progress for trial populations

Biomarkers progressively de-risk trials with smarter designs and targeted participant populations. By identifying patients with the specific biological features of a therapy target, researchers can reduce variability, improve statistical power and avoid enrolling individuals unlikely to benefit. This precision leads to smaller, faster and more cost-effective studies, with improved recruitment, clearer outcomes and fewer false negatives. It also allows for earlier go/no-go decisions, helping sponsors allocate resources more efficiently and avoid late-stage failures. 

For trial participants, biomarkers effectively improve the risk-benefit ratio for them with selection criteria to target patients most likely to respond to the therapy. 

Switching gears from stalling progression to potential cure

Biomarkers also signify the first significant step toward preventive and potentially curative approaches. In Alzheimer’s, for example, fluid and imaging biomarkers can detect pathology years before symptoms appear. This creates a window for early intervention before irreversible damage occurs. Patients may one day receive treatment not because they are sick, but because they are at high risk.

This marks a fundamental shift in the patient experience. Instead of managing inevitable decline, we can begin to talk about halting disease before it begins. Instead of generalised care, we can pinpoint tailored therapies based on biomarkers. And instead of uncertainty, patients gain clarity about their condition and their options. 

Biomarkers in the building—collaborating to catalyse innovation

Thankfully, innovation in the CNS and biomarker space is moving fast. But keeping up with the pace of innovation is a strategic imperative that requires concerted, cross-functional collaboration. Staying ahead means tracking emerging science and also translating it into trial-ready solutions in real time—even amending ongoing trial protocols if feasible.

ICON is poised at the forefront of this transformation with access to experts from all relevant biomarker domains and laboratory specialists under one roof. To capitalise on this expertise, we have created a formal internal biomarker forum to serve as a regular checkpoint for knowledge sharing, evaluating new technologies and aligning on trial strategy.

This ensures that ICON can deliver trials that evolve with the science, not behind it. In a field where the stakes are high and the timelines are tight, that kind of agility makes a difference.

For more information on how biomarkers are reshaping neurodegenerative disease research, watch our insightful webinar with industry experts. To learn how to integrate biomarker innovation into your trial design to keep up with the new era of CNS research, connect with us today. 

In this section

Connect with us